The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How

Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens

(2019) Ilias Karaiskos et al.   Expert Opinion on Drug Metabolism & Toxicology

International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)

(2019) Brian T. Tsuji et al.   PHARMACOTHERAPY

Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae

(2019) James A. McKinnell et al.   NEW ENGLAND JOURNAL OF MEDICINE

High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial

(2019) Astrid Pérez et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections

(2018) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vivo Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model

(2018) Kamilia Abdelraouf et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Ceftazidime-avibactam Salvage Therapy in Patients with Infections Caused by KPC-producing Klebsiella pneumoniae

(2018) Mario Tumbarello et al.   CLINICAL INFECTIOUS DISEASES

Management of KPC-producing Klebsiella pneumoniae infections

(2018) M. Bassetti et al.   CLINICAL MICROBIOLOGY AND INFECTION

Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia.

(2018) Aiden J. Plant et al.   Expert Review of Anti-Infective Therapy

Ceftolozane/tazobactam: place in therapy

(2018) Daniele Roberto Giacobbe et al.   Expert Review of Anti-Infective Therapy

Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections

(2018) Laura Escolà-Vergé et al.   INFECTION

Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection

(2018) Maddalena Giannella et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Fosfomycin Etest for Enterobacteriaceae: Interobserver and interlaboratory agreement

(2018) S.P. van Mens et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii

(2018) Harald Seifert et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection

(2018) Keith S. Kaye et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection

(2018) Alan R Noel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012–15

(2018) Krystyna M Kazmierczak et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15

(2018) Krystyna M Kazmierczak et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro evaluation of double-carbapenem combinations against OXA-48-producing Klebsiella pneumoniae isolates using time–kill studies

(2018) Irene Galani et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

(2018) Mical Paul et al.   LANCET INFECTIOUS DISEASES

Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial

(2018) Antoni Torres et al.   LANCET INFECTIOUS DISEASES

High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections

(2018) Ting-Ting Geng et al.   MEDICINE

Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations

(2018) Juri Katchanov et al.   PLoS One

Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa

(2018) Marc Xipell et al.   Journal of Global Antimicrobial Resistance

In vitro antibacterial effect of fosfomycin combination therapy against colistin-resistant Klebsiella pneumoniae

(2018) Wei Yu et al.   Infection and Drug Resistance

Activity of fosfomycin when tested against US contemporary bacterial isolates

(2018) Robert K. Flamm et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Discrepancies in fosfomycin susceptibility testing of KPC-producing Klebsiella pneumoniae with various commercial methods

(2018) Giulio Camarlinghi et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016

(2018) Irene Galani et al.   Eurosurveillance

Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis

(2018) Han Zhong et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Treatment outcomes of colistin and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial

(2018) Yaakov Dickstein et al.   CLINICAL INFECTIOUS DISEASES

IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs. Meropenem in the Treatment of Complicated Intra-Abdominal Infections

(2018) Joseph S Solomkin et al.   CLINICAL INFECTIOUS DISEASES

New Antibiotics for Pneumonia

(2018) Matteo Bassetti et al.   CLINICS IN CHEST MEDICINE

Rational approach in the management of P.aeruginosa infections

(2018) Matteo Bassetti et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience

(2018) Matteo Bassetti et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae

(2017) M. Souli et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility

(2017) Alexandre P. Zavascki et al.   Expert Review of Anti-Infective Therapy

Combination therapy for extensively-drug resistant gram-negative bacteria

(2017) Ilias Karaiskos et al.   Expert Review of Anti-Infective Therapy

Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges

(2017) G Poulakou et al.   Expert Review of Anti-Infective Therapy

Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach

(2017) Matteo Bassetti et al.   INTENSIVE CARE MEDICINE

In vitro antibacterial activity of fosfomycin combined with other antimicrobials against KPC-producing Klebsiella pneumoniae

(2017) Wei Yu et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia

(2017) Xinyu Qin et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients

(2017) Juan J. Castón et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Pharmacodynamics of colistin and fosfomycin: a ‘treasure trove’ combination combats KPC-producing Klebsiella pneumoniae

(2017) Miao Zhao et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection

(2017) Evelyn Shaw et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L

(2017) Senthil Natesan et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates

(2017) Valérie Denervaud-Tendon et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles

(2017) David M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp)

(2017) Alessandra Oliva et al.   JOURNAL OF INFECTION

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

(2017) Belén Gutiérrez-Gutiérrez et al.   LANCET INFECTIOUS DISEASES

Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study

(2017) Hajo Grundmann et al.   LANCET INFECTIOUS DISEASES

“Double carbapenem” and oral fosfomycin for the treatment of complicated urinary tract infections caused by bla NDM -harboring Enterobacteriaceae in kidney transplantation

(2017) Rossana Rosa et al.   Transplant Infectious Disease

Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering

(2017) Melissa D. Barnes et al.   mBio

Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial

(2017) Joseph Solomkin et al.   JAMA Surgery

Improved Outcomes with Plazomicin (PLZ) Compared with Colistin (CST) in Patients with Bloodstream Infections (BSI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE): Results from the CARE Study

(2017) James A McKinnell et al.   Open Forum Infectious Diseases

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects

(2016) David C. Griffith et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae

(2016) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae

(2016) James Albiero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii

(2016) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae

(2016) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient

(2016) Maria F. Mojica et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms: a case series from the compassionate-use program

(2016) Elizabeth Temkin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections

(2016) Juan José Castón et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

(2016) Florian M. Wagenlehner et al.   CLINICAL INFECTIOUS DISEASES

Dosing guidance for intravenous colistin in critically-ill patients

(2016) Roger L Nation et al.   CLINICAL INFECTIOUS DISEASES

Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

(2016) Andre C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

(2016) John E. Mazuski et al.   CLINICAL INFECTIOUS DISEASES

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.

(2016) Ryan K. Shields et al.   CLINICAL INFECTIOUS DISEASES

Colistin: still a lifesaver for the 21st century?

(2016) Ilias Karaiskos et al.   Expert Opinion on Drug Metabolism & Toxicology

Aminoglycoside Resistance

(2016) Yohei Doi et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration

(2016) Joseph L. Kuti et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature

(2016) Konstantinos Z. Vardakas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis

(2016) Oren Zusman et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study

(2016) Alexandre Brasseur et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam

(2016) Ravina Kullar et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Aminoglycoside-associated acute kidney injury in elderly patients with and without shock

(2016) Li-Zhen Ong et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae : a pooled analysis of Phase 3 clinical trials

(2016) Myra W. Popejoy et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment

(2016) Henri Merdjan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study

(2016) Yehuda Carmeli et al.   LANCET INFECTIOUS DISEASES

Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study

(2016) Yi-Yun Liu et al.   LANCET INFECTIOUS DISEASES

Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections

(2016) Wentao Ni et al.   MEDICINE

Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy

(2016) Derek N. Bremmer et al.   PHARMACOTHERAPY

Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock

(2016) Nicolas Allou et al.   Annals of Intensive Care

Once-daily aminoglycoside dosing: An update on current literature

(2015) M. S. Stankowicz et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Eravacycline (TP-434) Is Efficacious in Animal Models of Infection

(2015) Trudy H. Grossman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Antimicrobial Combinations against KPC-2-Producing Klebsiella pneumoniae in a Rat Model and Time-Kill Assay

(2015) Paula Virginia Michelon Toledo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of Fosfomycin in Critically Ill Patients

(2015) Suzanne L. Parker et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients

(2015) Ilias Karaiskos et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroAntibacterial Activity of the Ceftazidime-Avibactam Combination against Enterobacteriaceae, Including Strains with Well-Characterized β-Lactamases

(2015) Premavathy Levasseur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013

(2015) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum β-Lactamases, and Porin Mutations on theIn VitroActivity of Ceftazidime-Avibactam against Carbapenem-Resistant K. pneumoniae

(2015) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City

(2015) Amabel Lapuebla et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Colistin-associated Acute Kidney Injury in Severely Ill Patients: A Step Toward a Better Renal Care? A Prospective Cohort Study

(2015) Lidia Dalfino et al.   CLINICAL INFECTIOUS DISEASES

Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?

(2015) Roger L. Nation et al.   CLINICAL INFECTIOUS DISEASES

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

(2015) Joseph Solomkin et al.   CLINICAL INFECTIOUS DISEASES

Plazomicin: an investigational therapy for the treatment of urinary tract infections

(2015) Ilias Karaiskos et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Task force on management and prevention of Acinetobacter baumannii infections in the ICU

(2015) José Garnacho-Montero et al.   INTENSIVE CARE MEDICINE

The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments

(2015) Mahableshwar S. Albur et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections

(2015) Christina Routsi et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations

(2015) Claire Roger et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis

(2015) Claire Roger et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens

(2015) David P. Nicolau et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study

(2015) Mario Tumbarello et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitroevaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae

(2015) Laurent Poirel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia

(2015) Alan J. Xiao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers

(2015) Nobumitsu Tominaga et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases

(2015) Scott J. Hecker et al.   JOURNAL OF MEDICINAL CHEMISTRY

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)

(2015) Florian M Wagenlehner et al.   LANCET

Mechanisms of antimicrobial resistance in Gram-negative bacilli

(2015) Étienne Ruppé et al.   Annals of Intensive Care

Three Dimensional Checkerboard Synergy Analysis of Colistin, Meropenem, Tigecycline against Multidrug-Resistant Clinical Klebsiella pneumonia Isolates

(2015) Claudia Stein et al.   PLoS One

Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections

(2014) Rujipas Sirijatuphat et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase I, Open-Label, Safety and Pharmacokinetic Study To Assess Bronchopulmonary Disposition of Intravenous Eravacycline in Healthy Men and Women

(2014) Kevin P. Connors et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, from New York City

(2014) Marie Abdallah et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC

(2014) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of a Ceftazidime-Avibactam Combination in a Murine Model of Septicemia Caused by Enterobacteriaceae Species Producing AmpC or Extended-Spectrum β-Lactamases

(2014) Premavathy Levasseur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

KPC-Producing Klebsiella pneumoniae Strains That Harbor AAC(6′)-Ib Exhibit Intermediate Resistance to Amikacin

(2014) Derek N. Bremmer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Carbapenem-Resistant Klebsiella pneumoniae Strains Exhibit Diversity in Aminoglycoside-Modifying Enzymes, Which Exert Differing Effects on Plazomicin and Other Agents

(2014) Reem Almaghrabi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Plazomicin against 5,015 Gram-Negative and Gram-Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012

(2014) A. Walkty et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bactericidal Activity, Absence of Serum Effect, and Time-Kill Kinetics of Ceftazidime-Avibactam against β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

(2014) Tiffany R. Keepers et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of Clonality and Carbapenem Resistance Mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus Complex and Enterobacteriaceae Isolates Collected in European and Mediterranean Countries and Detection of Two Novel β-Lactamases, GES-22 and VIM-35

(2014) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroandIn VivoActivities of Tigecycline-Colistin Combination Therapies against Carbapenem-Resistant Enterobacteriaceae

(2014) Jonathan W. Betts et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems

(2014) George L. Daikos et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011)

(2014) Robert K. Flamm et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia

(2014) C. Burdet et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014

(2014) M. Monaco et al.   Eurosurveillance

Eravacycline for the treatment of intra-abdominal infections

(2014) Matteo Bassetti et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Is there a future for tigecycline?

(2014) Matteo Bassetti et al.   INTENSIVE CARE MEDICINE

Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen

(2014) Etienne de Montmollin et al.   INTENSIVE CARE MEDICINE

Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections

(2014) Matthew E. Falagas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)

(2014) David J. Farrell et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae

(2014) M. Gonzalez-Padilla et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae

(2014) D. van Duin et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In VitroPharmacodynamics of Polymyxin B and Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii

(2013) Mao Hagihara et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effectiveness of a Double-Carbapenem Regimen for Infections in Humans Due to Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae

(2013) Helen Giamarellou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of Fosfomycin against a Collection of Clinical Pseudomonas aeruginosa Isolates from 16 Spanish Hospitals: Establishing the Validity of Standard Broth Microdilution as Susceptibility Testing Method

(2013) María Díez-Aguilar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia

(2013) Julio Ramirez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial

(2013) Emanuele Durante-Mangoni et al.   CLINICAL INFECTIOUS DISEASES

What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review

(2013) Suzanne Parker et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria

(2013) Konstantinos Pontikis et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases

(2013) L Silvia Munoz-Price et al.   LANCET INFECTIOUS DISEASES

KPC - 3 Klebsiella pneumoniaeST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: analysis of a case series of 30 patients

(2013) Paola Di Carlo et al.   BMC Anesthesiology

In VitroAntibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates

(2012) Premavathy Levasseur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy

(2012) M. Tumbarello et al.   CLINICAL INFECTIOUS DISEASES

Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions

(2012) L. S. Tzouvelekis et al.   CLINICAL MICROBIOLOGY REVIEWS

Treatment and Clinical Outcomes of Urinary Tract Infections Caused by KPC-Producing Enterobacteriaceae in a Retrospective Cohort

(2012) Bryan T. Alexander et al.   CLINICAL THERAPEUTICS

Bloodstream infections caused by carbapenemase-producingKlebsiella pneumoniae: a clinical perspective

(2012) George L Daikos et al.   Expert Review of Anti-Infective Therapy

Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin

(2012) George G Zhanel et al.   Expert Review of Anti-Infective Therapy

Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases

(2012) D. E. Karageorgopoulos et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects

(2012) G. Chandorkar et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of Plazomicin (ACHN-490) against MDR clinical isolates ofKlebsiella pneumoniae, Escherichia coli, andEnterobacterspp. from Athens, Greece

(2012) Irene Galani et al.   JOURNAL OF CHEMOTHERAPY

Assessment of Antimicrobial Combinations for Klebsiella pneumoniae Carbapenemase–Producing K. pneumoniae

(2012) Elizabeth B. Hirsch et al.   JOURNAL OF INFECTIOUS DISEASES

Pharmacokinetics and Safety of Single and Multiple Doses of ACHN-490 Injection Administered Intravenously in Healthy Subjects

(2011) Robert T. Cass et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroInteractions of Antimicrobial Combinations with Fosfomycin against KPC-2-Producing Klebsiella pneumoniae and Protection of Resistance Development

(2011) Maria Souli et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae

(2011) Catharine C. Bulik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative Effectiveness of Aminoglycosides, Polymyxin B, and Tigecycline for Clearance of Carbapenem-Resistant Klebsiella pneumoniae from Urine

(2011) Michael J. Satlin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates

(2011) G. Samonis et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Pharmacokinetic and pharmacodynamic evaluation of tigecycline

(2011) Helen Giamarellou et al.   Expert Opinion on Drug Metabolism & Toxicology

Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time–kill assay

(2011) Spyros Pournaras et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity

(2011) Ricardo Gálvez et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae

(2011) B. Bercot et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fosfomycin: Efficacy against infections caused by multidrug-resistant bacteria

(2011) Aurélien Dinh et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa

(2010) B. Moya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues

(2010) V. Miriagou et al.   CLINICAL MICROBIOLOGY AND INFECTION

Adverse events associated with intravenous fosfomycin

(2010) Amélie Florent et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates

(2010) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Extracellular concentrations of fosfomycin in lung tissue of septic patients

(2010) V. Matzi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City

(2010) D. Landman et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Prospective Observational Study of the Impact of VIM-1 Metallo- -Lactamase on the Outcome of Patients with Klebsiella pneumoniae Bloodstream Infections

(2009) G. L. Daikos et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ACHN-490, a Neoglycoside with Potent In Vitro Activity Against Multidrug-Resistant Klebsiella pneumoniae Isolates

(2009) A. Endimiani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria

(2009) D. Plachouras et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation

(2009) A. Michalopoulos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Multidrug-Resistant Gram-Negative Infections

(2009) Helen Giamarellou et al.   DRUGS

Combination Antimicrobial Treatment Versus Monotherapy: The Contribution of Meta-analyses

(2009) Mical Paul et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint

(2009) Olaf Burkhardt et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model

(2009) P. Koomanachai et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

(2008) Helen W. Boucher et al.   CLINICAL INFECTIOUS DISEASES

Screening for resistant gram-negative microorganisms to guide empiric therapy of subsequent infection

(2008) Evangelos Papadomichelakis et al.   INTENSIVE CARE MEDICINE